FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890743199> ?p ?o ?g. }

• W2890743199 abstract "Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-month median survival. Several tyrosine kinase inhibitors (TKIs) are currently under investigation as an alternative treatment option for cholangiocarcinoma. Thus, the report of personalized selection of effective inhibitor and case outcome are of clinical interest.Here we report a case of aggressive metastatic cholangiocarcinoma (MCC) in 72-year-old man, sequentially treated with two targeted chemotherapies. Initially disease quickly progressed during best clinical practice care (gemcitabine in combination with cisplatin or capecitabine), which was accompanied by significant decrease of life quality. Monotherapy with TKI sorafenib was prescribed to the patient, which resulted in stabilization of tumor growth and elimination of pain. The choice of the inhibitor was made based on high-throughput screening of gene expression in the patient's tumor biopsy, utilized by Oncobox platform to build a personalized rating of potentially effective target therapies. However, time to progression after start of sorafenib administration did not exceed 6 months and the regimen was changed to monotherapy with Pazopanib, another TKI predicted to be effective for this patient according to the same molecular test. It resulted in disease progression according to RECIST with simultaneous elimination of sorafenib side effects such as rash and hand-foot syndrome. After 2 years from the diagnosis of MCC the patient was alive and physically active, which is substantially longer than median survival for standard therapy.This case evidences that sequential personalized prescription of different TKIs may show promising efficacy in terms of survival and quality of life in MCC." @default.
• W2890743199 created "2018-09-27" @default.
• W2890743199 creator A5027499841 @default.
• W2890743199 creator A5038240049 @default.
• W2890743199 creator A5043771424 @default.
• W2890743199 creator A5046602425 @default.
• W2890743199 creator A5050164113 @default.
• W2890743199 creator A5054564180 @default.
• W2890743199 creator A5057411359 @default.
• W2890743199 creator A5064275932 @default.
• W2890743199 creator A5079640410 @default.
• W2890743199 date "2018-09-06" @default.
• W2890743199 modified "2023-10-11" @default.
• W2890743199 title "Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma" @default.
• W2890743199 cites W1562928769 @default.
• W2890743199 cites W1992361007 @default.
• W2890743199 cites W1996388792 @default.
• W2890743199 cites W1997239834 @default.
• W2890743199 cites W2001620773 @default.
• W2890743199 cites W2028700227 @default.
• W2890743199 cites W2037793000 @default.
• W2890743199 cites W2063432158 @default.
• W2890743199 cites W2068110847 @default.
• W2890743199 cites W2085417547 @default.
• W2890743199 cites W2089512714 @default.
• W2890743199 cites W2115261608 @default.
• W2890743199 cites W2117674153 @default.
• W2890743199 cites W2139213909 @default.
• W2890743199 cites W2140805747 @default.
• W2890743199 cites W2141078344 @default.
• W2890743199 cites W2142742274 @default.
• W2890743199 cites W2159654470 @default.
• W2890743199 cites W2168488626 @default.
• W2890743199 cites W2470260050 @default.
• W2890743199 cites W2536352906 @default.
• W2890743199 cites W2560638037 @default.
• W2890743199 cites W2568042564 @default.
• W2890743199 cites W2594440590 @default.
• W2890743199 cites W2597378660 @default.
• W2890743199 cites W2604241833 @default.
• W2890743199 cites W2608084876 @default.
• W2890743199 cites W2732767128 @default.
• W2890743199 cites W2761719273 @default.
• W2890743199 cites W2805366761 @default.
• W2890743199 cites W2805456004 @default.
• W2890743199 doi "https://doi.org/10.1186/s40164-018-0113-x" @default.
• W2890743199 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6127913" @default.
• W2890743199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30202637" @default.
• W2890743199 hasPublicationYear "2018" @default.
• W2890743199 type Work @default.
• W2890743199 sameAs 2890743199 @default.
• W2890743199 citedByCount "31" @default.
• W2890743199 countsByYear W28907431992018 @default.
• W2890743199 countsByYear W28907431992019 @default.
• W2890743199 countsByYear W28907431992020 @default.
• W2890743199 countsByYear W28907431992021 @default.
• W2890743199 countsByYear W28907431992022 @default.
• W2890743199 crossrefType "journal-article" @default.
• W2890743199 hasAuthorship W2890743199A5027499841 @default.
• W2890743199 hasAuthorship W2890743199A5038240049 @default.
• W2890743199 hasAuthorship W2890743199A5043771424 @default.
• W2890743199 hasAuthorship W2890743199A5046602425 @default.
• W2890743199 hasAuthorship W2890743199A5050164113 @default.
• W2890743199 hasAuthorship W2890743199A5054564180 @default.
• W2890743199 hasAuthorship W2890743199A5057411359 @default.
• W2890743199 hasAuthorship W2890743199A5064275932 @default.
• W2890743199 hasAuthorship W2890743199A5079640410 @default.
• W2890743199 hasBestOaLocation W28907431991 @default.
• W2890743199 hasConcept C121608353 @default.
• W2890743199 hasConcept C126322002 @default.
• W2890743199 hasConcept C143998085 @default.
• W2890743199 hasConcept C184235292 @default.
• W2890743199 hasConcept C197934379 @default.
• W2890743199 hasConcept C2776248978 @default.
• W2890743199 hasConcept C2777909004 @default.
• W2890743199 hasConcept C2778019345 @default.
• W2890743199 hasConcept C2778439243 @default.
• W2890743199 hasConcept C2778472372 @default.
• W2890743199 hasConcept C2778570526 @default.
• W2890743199 hasConcept C2778695046 @default.
• W2890743199 hasConcept C2779490328 @default.
• W2890743199 hasConcept C2780258809 @default.
• W2890743199 hasConcept C2781187634 @default.
• W2890743199 hasConcept C2781413609 @default.
• W2890743199 hasConcept C526805850 @default.
• W2890743199 hasConcept C57074206 @default.
• W2890743199 hasConcept C71924100 @default.
• W2890743199 hasConcept C86803240 @default.
• W2890743199 hasConcept C95444343 @default.
• W2890743199 hasConceptScore W2890743199C121608353 @default.
• W2890743199 hasConceptScore W2890743199C126322002 @default.
• W2890743199 hasConceptScore W2890743199C143998085 @default.
• W2890743199 hasConceptScore W2890743199C184235292 @default.
• W2890743199 hasConceptScore W2890743199C197934379 @default.
• W2890743199 hasConceptScore W2890743199C2776248978 @default.
• W2890743199 hasConceptScore W2890743199C2777909004 @default.
• W2890743199 hasConceptScore W2890743199C2778019345 @default.
• W2890743199 hasConceptScore W2890743199C2778439243 @default.
• W2890743199 hasConceptScore W2890743199C2778472372 @default.
• W2890743199 hasConceptScore W2890743199C2778570526 @default.

• next